Advancing women's health via FDA Critical Path Initiative

A Parekh; W Sanhai; S Marts; K Uhl

doi:10.1016/j.ddtec.2007.10.014

Advancing women's health via FDA Critical Path Initiative

Drug Discov Today Technol. 2007 Winter;4(2):69-73. doi: 10.1016/j.ddtec.2007.10.014.

Authors

A Parekh¹, W Sanhai², S Marts³, K Uhl⁴

Affiliations

¹ Food and Drug Administration, Office of Women's Health, 5600 Fishers Lane, Rockville MD 20857, USA. Electronic address:ameeta.parekh@fda.hhs.gov.
² Food and Drug Administration, Office of the Commissioner, 5600 Fishers Lane, Rockville MD 20857, USA.
³ Society for Women's Health Research, 1025 Connecticut Avenue, N.W., Washington, DC 20036, USA.
⁴ Food and Drug Administration, Office of Women's Health, 5600 Fishers Lane, Rockville MD 20857, USA.

PMID: 24980844
DOI: 10.1016/j.ddtec.2007.10.014

Abstract

Studying sex and gender differences is critical to understanding diseases that affect women solely, disproportionately or differently from men. Although inclusion of both sexes is essential in clinical research, advanced technology and analysis methods offer tools to define complex biological and physicochemical differences and improve prevention, diagnosis and treatments for diseases in women and men. This paper identifies the potential for biomarker development, pharmacogenetics and bioinformatics in research under the FDA Critical Path Initiative.: